Autolus (AUTL) CDO details long-dated options and RSU awards in Form 3

Rhea-AI Filing Summary

Autolus Therapeutics plc Chief Development Officer Will Matthias filed an initial ownership report showing equity awards linked to American Depositary Shares. He holds multiple share options with exercise prices of $3.63, $1.89, and $1.46 expiring between 2034 and 2036, plus restricted share units that vest in four equal annual installments starting on January 26, 2027. Each RSU represents a contingent right to receive one American Depositary Share.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Will Matthias

(Last) (First) (Middle)

C/O AUTOLUS THERAPEUTICS PLC

THE MEDIAWORKS, 191 WOOD LN, WHITE CITY

(Street)

LONDON W12 7FP

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(1)	09/30/2034	American Depositary Shares	800,000	$3.63	D
Share Option (right to buy)	(2)	03/14/2035	American Depositary Shares	250,000	$1.89	D
Share Option (right to buy)	(3)	01/26/2036	American Depositary Shares	375,000	$1.46	D
Restricted Share Units	(4)	(4)	American Depositary Shares	83,300	(5)	D

Explanation of Responses:

1. This option vested 25% on September 30, 2025 and the remainder vests in 36 equal monthly installments thereafter.

2. This option vested 25% on March 14, 2026 and the remainder vests in 36 equal monthly installments thereafter.

3. This option vests 25% on January 26, 2027 and the remainder vests in 36 equal monthly installments thereafter.

4. The restricted share units ("RSUs") vest in four equal annual installments commencing on January 26, 2027.

5. Each RSU represents a contingent right to receive one Issuer American Depositary Share.

	/s/ Matthias Will	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Autolus (AUTL) Form 3 filing by Will Matthias show?

The Form 3 shows Chief Development Officer Will Matthias’ existing equity awards. It lists several share option grants and restricted share units tied to Autolus American Depositary Shares, including exercise prices, expiration dates, and detailed vesting schedules for each award.

Did Autolus executive Will Matthias buy or sell AUTL shares in this Form 3?

No buy or sell activity is reported; this Form 3 lists holdings. It discloses existing share options and restricted share units rather than new open-market purchases or sales, providing a baseline view of his equity-based compensation in Autolus Therapeutics.

What option awards for AUTL does Will Matthias report in the Form 3?

He reports three option grants over American Depositary Shares with exercise prices of $3.63, $1.89, and $1.46. These options expire in 2034, 2035, and 2036, with vesting schedules beginning on specific dates and then vesting monthly thereafter.

How do the restricted share units for AUTL vest for Will Matthias?

The restricted share units vest in four equal annual installments starting on January 26, 2027. This means one-quarter of the RSUs convert each year into American Depositary Shares, aligning his compensation with Autolus Therapeutics’ long-term performance over several years.

What does each restricted share unit represent in the Autolus Form 3?

Each restricted share unit represents a contingent right to receive one Autolus American Depositary Share. Delivery depends on vesting conditions being met over time, so the RSUs convert into actual ADSs only as the scheduled vesting dates are reached.

What is the significance of the long option expirations reported for AUTL?

The options expire between 2034 and 2036, indicating long-dated incentives. These extended expiration dates give the executive many years during which options can potentially be exercised, reinforcing a long-term alignment with Autolus Therapeutics’ share performance.